BACKGROUND: Pseudomonas aeruginosa bacteremia is a serious and life-threatening infection associated with high mortality. Among the multitude of virulence determinants possessed by P. aeruginosa, the type 3 secretion system has been implicated with more acute and invasive infection in respiratory diseases. However, the relationship between the type 3 secretion system and clinical outcomes in P. aeruginosa bacteremia has not been investigated. OBJECTIVES: To determine the association between the type 3 secretion system virulence factor in P. aeruginosa bloodstream infection and 30-day mortality. DESIGN: Retrospective analysis of 85 cases of P. aeruginosa bacteremia. SETTING: Tertiary care hospital. INTERVENTIONS: Bacterial isolates were assayed in vitro for secretion of type 3 exotoxins (ExoU, ExoT, and ExoS). Strain relatedness was analyzed using randomly amplified polymorphic DNA polymerase chain reaction genotyping. Antimicrobial susceptibilities were determined by means of the Kirby-Bauer disk-diffusion test. MEASUREMENTS AND MAIN RESULTS: At least one of the type 3 secretion system proteins was detected in 37 out of the 85 isolates (44%). Septic shock was identified in 43% of bacteremic patients with type 3 secretion system+ isolates compared to 23% of patients with type 3 secretion system- isolates (p = .12). A high frequency of resistance in the type 3 secretion system+ isolates was observed to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%). There was a significant difference in the 30-day cumulative probability of death after bacteremia between secretors and nonsecretors (p = .02). None of the type 3 secretion system+ patients who survived the first 30 days had a P. aeruginosa isolate which exhibited ExoU phenotype. CONCLUSIONS: The expression of type 3 secretion system exotoxins in bacteremic isolates of P. aeruginosa confers poor clinical outcomes independent of antibiotic susceptibility profile.
BACKGROUND:Pseudomonas aeruginosabacteremia is a serious and life-threatening infection associated with high mortality. Among the multitude of virulence determinants possessed by P. aeruginosa, the type 3 secretion system has been implicated with more acute and invasive infection in respiratory diseases. However, the relationship between the type 3 secretion system and clinical outcomes in P. aeruginosa bacteremia has not been investigated. OBJECTIVES: To determine the association between the type 3 secretion system virulence factor in P. aeruginosa bloodstream infection and 30-day mortality. DESIGN: Retrospective analysis of 85 cases of P. aeruginosa bacteremia. SETTING: Tertiary care hospital. INTERVENTIONS: Bacterial isolates were assayed in vitro for secretion of type 3 exotoxins (ExoU, ExoT, and ExoS). Strain relatedness was analyzed using randomly amplified polymorphic DNA polymerase chain reaction genotyping. Antimicrobial susceptibilities were determined by means of the Kirby-Bauer disk-diffusion test. MEASUREMENTS AND MAIN RESULTS: At least one of the type 3 secretion system proteins was detected in 37 out of the 85 isolates (44%). Septic shock was identified in 43% of bacteremic patients with type 3 secretion system+ isolates compared to 23% of patients with type 3 secretion system- isolates (p = .12). A high frequency of resistance in the type 3 secretion system+ isolates was observed to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%). There was a significant difference in the 30-day cumulative probability of death after bacteremia between secretors and nonsecretors (p = .02). None of the type 3 secretion system+ patients who survived the first 30 days had a P. aeruginosa isolate which exhibited ExoU phenotype. CONCLUSIONS: The expression of type 3 secretion system exotoxins in bacteremic isolates of P. aeruginosa confers poor clinical outcomes independent of antibiotic susceptibility profile.
Authors: Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden Journal: Antimicrob Agents Chemother Date: 2003-09 Impact factor: 5.191
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: A Roy-Burman; R H Savel; S Racine; B L Swanson; N S Revadigar; J Fujimoto; T Sawa; D W Frank; J P Wiener-Kronish Journal: J Infect Dis Date: 2001-05-17 Impact factor: 5.226
Authors: Alan R Hauser; Enesha Cobb; Maria Bodi; Dolors Mariscal; Jordi Vallés; Joanne N Engel; Jordi Rello Journal: Crit Care Med Date: 2002-03 Impact factor: 7.598
Authors: J M Kim; E S Park; J S Jeong; K M Kim; J M Kim; H S Oh; S W Yoon; H S Chang; K H Chang; S I Lee; M S Lee; J H Song; M W Kang; S C Park; K W Choe; C H Pai Journal: Am J Infect Control Date: 2000-12 Impact factor: 2.918
Authors: Philippe Berthelot; Ina Attree; Patrick Plésiat; Jacqueline Chabert; Sophie de Bentzmann; Bruno Pozzetto; Florence Grattard Journal: J Infect Dis Date: 2003-07-23 Impact factor: 5.226
Authors: David M Anderson; Jimmy B Feix; Andrew L Monroe; Francis C Peterson; Brian F Volkman; Arthur L Haas; Dara W Frank Journal: J Biol Chem Date: 2013-08-01 Impact factor: 5.157
Authors: Nicholas O Bowlin; John D Williams; Claire A Knoten; Matthew C Torhan; Tommy F Tashjian; Bing Li; Daniel Aiello; Joan Mecsas; Alan R Hauser; Norton P Peet; Terry L Bowlin; Donald T Moir Journal: Antimicrob Agents Chemother Date: 2014-01-27 Impact factor: 5.191